David C. Kaslow

TL;DR: A three-dose vaccination with RTS,S/AS01 was initially protective against clinical malaria, but this result was offset by rebound in later years in areas with higher-than-average exposure to malaria parasites.

TL;DR: The vaccines were well tolerated and immunogenic, with the DDM-ME TRAP regimen producing stronger ex vivo IFN-γ ELISPOT responses thanDDM-CS, and partial protection against P. falciparum sporozoite challenge in the present study.

TL;DR: The World Health Organization convened the first RSV vaccine consultation in 15 years on the 23rd and 24th of March, 2015 in Geneva, Switzerland to provide guidance on clinical endpoints and development pathways for vaccine trials with a focus on considerations of low- and middle-income countries.

TL;DR: This Guidance offers 22 concrete recommendations that provide a roadmap for the ethically responsible, socially just, and respectful inclusion of the interests of pregnant women in the development and deployment of vaccines against emerging pathogens.

TL;DR: More work is required to understand the global disease burden of GBS-associated stillbirths, and to develop quality-assured standardized antibody assays to identify correlates of protection, as well as to address gaps identified in each of these areas.